What is NeuroOne Medical Technologies Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. NeuroOne Medical Technologies's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. NeuroOne Medical Technologies's Operating Income for the
three
months ended in Mar. 2024 was $ -2.89 Mil. NeuroOne Medical Technologies's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
NeuroOne Medical Technologies has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NeuroOne Medical Technologies Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies (NAS:NMTC) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
NeuroOne Medical Technologies's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-2.89 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.00 Mil.
NeuroOne Medical Technologies's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| NeuroOne Medical Technologies had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. NeuroOne Medical Technologies Corp has enough cash to cover all of its debt. Its financial situation is stable.
NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description
Traded in Other Exchanges
N/A
Address
7599 Anagram Dr., Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Executives
| Mark Christianson |
10 percent owner, officer: VP, Business Dev and Marketing |
10006 LIATRIS LANE, EDEN PRAIRIE MN 55347 |
| Ronald W. Mcclurg |
officer: Chief Financial Officer |
C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344 |
| David A Rosa |
director, officer: CEO and President |
10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343 |
| Hijaz Haris |
officer: VP of Marketing |
C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344 |
| Morgan C. Frank |
10 percent owner |
2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907 |
| Manchester Management Co Llc |
10 percent owner |
3 WEST HILL PLACE, BOSTON MA 02110 |
| Manchester Explorer, L.p. |
10 percent owner |
MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114 |
| James E Besser |
10 percent owner |
3 WEST HILL PLACE, BOSTON MA 02114 |
| Manchester Management Pr, Llc |
10 percent owner |
3 WEST HILL PLACE, BOSTON MA 02114 |
| Edward Andrle |
director |
C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344 |
| Wade Fredrickson |
10 percent owner |
10006 LIATRIS LANE, EDEN PRAIRIE MN 55347 |
| Steve Mertens |
officer: Chief Technology Officer |
10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343 |
| Scott Heuler |
officer: Vice President of Sales |
10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343 |
| Paul Buckman |
director |
12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402 |
| Suraj Kalia |
director |
10006 LIATRIS LANE, EDEN PRAIRIE MN 55347 |
NeuroOne Medical Technologies (NeuroOne Medical Technologies) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NMTC has been successfully added to your 